<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03444948</url>
  </required_header>
  <id_info>
    <org_study_id>2018-7508</org_study_id>
    <nct_id>NCT03444948</nct_id>
  </id_info>
  <brief_title>A Clinical Study of EUS-RFA for Inoperable Pancreatic Ductal Adenocarcinoma</brief_title>
  <official_title>A Phase II Prospective Randomised Clinical Study of Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) for Inoperable Pancreatic Ductal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess if endoscopic ultrasound-guided radiofrequency ablation application in patients
      with inoperable pancreatic cancer confers survival benefit when compared to patients
      receiving standard medical care.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>at time of death on average 10months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>1 month</time_frame>
    <description>Quality of life questionnaire DDQ15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Time of death on average 10 months</time_frame>
    <description>Quality of life questionnaire DDQ15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain reduction</measure>
    <time_frame>1 month</time_frame>
    <description>Likert Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain reduction</measure>
    <time_frame>Time of death on average 10months</time_frame>
    <description>Likert Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumour Size</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitoring of Adverse reactions</measure>
    <time_frame>At time of death on average 10months</time_frame>
    <description>Number of participants with treatment-related adverse events will be recorded</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>3 radiofrequency ablation procedures + standard medical care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>standard medical care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EUS-RFA using Habib Tm as a probe</intervention_name>
    <description>3 course of EUS-RFA</description>
    <arm_group_label>3 radiofrequency ablation procedures + standard medical care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard therapy</intervention_name>
    <description>Standard medical care</description>
    <arm_group_label>standard medical care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients above 18 years of age.

          -  A cytological / histological diagnosis of inoperable PDAC based on multidisciplinary
             review of cross-sectional imaging and cytology / histology results.

          -  Patients ought to be fit enough to be considered for the study (ECOG performance
             status 0, 1 or 2)

          -  Patients who have commenced chemotherapy are not excluded from the study

          -  Patients capable of giving informed consent

          -  Negative blood pregnancy test for women of childbearing potential

          -  Willingness and ability to comply with all protocol requirements including scheduled
             visits, treatment plans, laboratory tests and other study procedures.

        Exclusion Criteria:

          -  ECOG performance status 3 or 4

          -  Life expectancy less than 3 months (including liver metastases, carcinomatosis)

          -  Prior investigational drugs within the last 30 days

          -  Known infection with human immunodeficiency virus (HIV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anand V Sahai, MD</last_name>
    <phone>514 890 8000</phone>
    <phone_ext>34373</phone_ext>
    <email>anand.sahai@sympatico.ca</email>
  </overall_contact>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2017</study_first_submitted>
  <study_first_submitted_qc>February 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2018</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

